DNA-PK is a key c-NHEJ protein, with preclinical DNA-PK inhibitors demonstrating potent antitumoral activity by increasing the sensitivity of various cancer cell lines to DSBs induced by chemo/radiotherapy [188,189,190]. This evidence concerns the gene PRKDC and cancer.